• Kyodo

  • SHARE

Japanese drugmaker Rohto Pharmaceutical Co. said Thursday it plans to launch a clinical trial using stem cells to develop a treatment for severe cases of COVID-19, the respiratory illness caused by the novel coronavirus.

The Osaka-based company said the trial will use mesenchymal stem cells created from human adipose tissue and the clinical test with stem cells will be the first of its kind in Japan.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW